Regulation of cell growth by selective COX-2 inhibitors in oral carcinoma cell lines

Prostaglandins and Other Lipid Mediators

Volumn 72, Issue 3-4, 2003, Pages 115-130

  Yang, C Y ^a   Meng, C L ^a   Liao, C L ^b   Wong, P Y K ^c  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cell growth; GCOX 2; Oral cancer

Indexed keywords

3 (3 FLUOROPHENYL) 5,5 DIMETHYL 4 (4 METHYLSULFONYLPHENYL) 2(5H) FURANONE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SELECTIVITY; FIBROBLAST; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; IC 50; MOUTH CARCINOMA; PROSTAGLANDIN SYNTHESIS;

EID: 0242321253     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-8823(03)00053-4     Document Type: Article

References (64)

1. Karmali R.A., Choi K., Otter G., Schmid F. Eicosanoids and metastasis: experimental aspects in Lewis lung carcinoma. Cancer Biochem. Biophys. 9:1986;97-104.
2. Danon A., Zenser T.V., Thomasson D.L., Davis B.B. Eicosanoid synthesis by cultured human urothelial cells: potential role in bladder cancer. Cancer Res. 46:1986;5676-5681.
3. Vanderveen E.E., Grekin R.C., Swanson N.A., Kragballe K. Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern. Arch Dermatol. 122:1986;407-412.
4. Levine L., Hinkle P.M., Voelkel E.F., Tashjian A.H. Jr. Prostaglandin production by mouse fibrosarcoma cells in culture: inhibition by indomethacin and aspirin. Biochem. Biophys. Res. Commun. 47:1972;888-896.
5. Goldhaber P. Enhancement of bone resorption in tissue culture by mouse fibrosarcoma. Proc. Am. Assoc. Cancer Res. 3:1960;113.
6. Prasad K.N. Morphological differentiation induced by prostaglandin in mouse neuroblastoma cells in culture. Nat. New Biol. 236:1972;49-52.
7. 2-dibutyryl adenosine 3′,5′-cyclic monophosphate. FEBS Lett. 36:1973;193-198.
8. 2. Cancer Res. 46:1986;3364-3366.
9. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., Dubois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188.
10. Reed G.A. Oxidation of environmental carcinogens by prostaglandin H synthase. J. Environ. Sci. Health C: Environ. Carcinogen Rev. C6:1988;223-259.
11. Flammang T.J., Yamazoe Y., Benson R.W.et al. Arachidonic acid-dependent peroxidative activation of carcinogenic arylamines by extrahepatic human tissue microsomes. Cancer Res. 49:1989;1977-1982.
12. Marnett L.J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 52:1992;5575-5589.
13. Marnett L.J. Prostaglandin synthase-mediated metabolism of carcinogens and a potential role for peroxyl radicals as positive intermediates. Environ. Health Perspect. 88:1990;5-12.
14. Hla T., Neilson K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U.S.A. 89:1992;7384-7388.
15. O'Neill G., Hutchinson A.F. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 330:1993;156-160.
16. Williams C.W., DuBois R.N. Prostaglandin endoperoxide synthase: why two isoforms? Am. J. Physiol. 270:1996;G393-G400.
17. Kang R.Y., Freire M.J., Sigal E., Chu C.Q. Expression of cyclooxygenase-2 in human and animal model of rheumatoid arthritis. Br. J. Rheumatol. 35:1996;711-718.
18. Singer I.I., Kawka D.W., Schloemann S., Tessner T., Riehl T., Stenson W.F. Cyclooxygenase-2 is induced in clonic epithelial cells in inflammatory bowel disease. Gastroenterology. 115:1998;297-306.
19. Sawaoka H., Kawanto S., Tsuji S.et al. Helicobacter pylori infection induces cyclooxygenase 2 gene expression in human gastric mucosa. Prostaglandin Leukot Essent Fatty Acids. 59:1998;313-316.
20. Charles E.E., Robert J.C., Aramandla R., Francis M.G., Suzanne F., Raymond D. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188.
21. Sano H., Kawahito Y., Wilder R.L.et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55:1995;3785-3789.
22. Fujita T., Matsui M., Takaku K.et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res. 58:1998;4823-4826.
23. Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst. 90:1998;455-460.
24. Ristimaki A., Honkanen N., Jankala H., Sipponen P., Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1997;1276-1280.
25. Katja C.Z., Mario S., Artur-Aron W., Franz B., Helmut E.G., Karsten S. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59:1999;198-204.
26. Hida T., Yatabe Y., Achiwa H.et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specially in adenocarcinomas. Cancer Res. 58:1998;3761-3764.
27. Koga H., Sakisaka S., Ohishi M.et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology. 29:1999;688-696.
28. Tucker O.N., Dannenberg A.J., Yang E.K.et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59:1999;987-990.
29. Sawaoka H., Kawano S., Tsujii S.et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol. 274:1998;G1061-G1067.
30. Lui X.H., Yao S., Kirschenbaum A., Levine A.C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 58:1998;4245-4249.
31. Sheng H., Shao J., Kirkland S.C.et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Investig. 99:1997;2254-2259.
32. Kawamori T., Rao C.V., Seibert K., Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenesis-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412.
33. Yang C.Y., Meng C.L. Regulation of PG synthase by EGF and PDGF in human oral, breast, stomach, and fibrosarcoma cancer cell lines. J. Dent Res. 73:1994;1407-1415.
34. Van Wyk C.W., Olivier A., De Miranda C.M., van der Bijl P., Grobler-Rabie A.F. Observations on the effect of areca nut extracts on oral fibroblast proliferation. J. Oral. Pathol. Med. 23:1994;145-148.
35. Meng C.L., Chao C.F., Tu C.L., Chang L.C. Establishment and characterization of a human oral epidermoid carcinoma cell line. Chin. Dent J. 4:1984;103-105.
36. Rosenberg L., Palmer J.R., Zauber A.G., Washauer M.E., Stolley P.D., Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of the large-bowel cancer. J. Natl. Cancer Inst. 83:1991;355-358.
37. Sacks F.M., Pfeffer M.A., Moye L.A.et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335:1996;1001-1009.
38. Thun M.J., Namboodiri M.M., Health C.W.J. Aspirin use and reduced risk of fetal colon cancer. N. Engl. J. Med. 325:1991;1593-1596.
39. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. USA. 96:1999;7563-7568.
40. Riendeau D., Charleson S., Cromlish W., Mancini J.A., Wong E., Guay J. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can. J. Physiol. Pharmacol. 75:1997;1088-1095.
41. Riendeau D.V., Percival M.D., Boyce C.et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. 121:1997;105-117.
42. -/- mice. Brain Res. 825:1999;86-94.
43. Li S., Ballou L.R., Morham S.G., Blatteis C.M. Cyclooxygenase-2 mediates the febrile response of mice to interleukin-1β Brain Res. 910:2001;163-173.
44. Seibert K., Zhang Y., Leahy K.et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA. 91:1994;12013-12017.
45. Reddy B.S., Rao C.V., Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 56:1996;4566-4569.
46. Bol D.K., Rowley R.B., Ho C.P.et al. Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res. 62:2002;2516-2521.
47. Wenger F.A., Kilian M., Bisevac M.et al. Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters. Clin. Exp. Metastasis. 19:2002;681-687.
48. Arico S., Pattingre S., Bauvy C.et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Biol. Chem. 277:2002;27613-27621.
49. Tucker O.N., Dannenberg A.J., Yang E.K.et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59:1999;987-990.
50. Ding X.Z., Tong W.G., Adrian T.E. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 20:2000;2625-2632.
51. Elder D.J.E., Halton D.E., Crew T.E., Paraskeva C. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int. J. Cancer. 86:2000;553-560.
52. Lee D.W., Sung M.W., Park S.W.et al. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res. 22:2002;2089-2096.
53. Chang H.C., Weng C.F. Cyclooxygenase-2 level and culture conditions influence NS-398-induced apoptosis and caspase activation in lung cancer cells. Oncol. Rep. 8:2001;1321-1325.
54. Abiru S., Nakao K., Ichikawa T. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology. 35:2002;1117-1124.
55. Schwenger P., Bellosta P., Vietor I., Basilico C., Skolnik E.Y., Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-jun N-terminal kinase/stress- activated protein kinase activation. Proc. Natl. Acad. Sci. USA. 94:1997;2869-2873.
56. Elder D., Hague A., Hicks D.J., Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res. 56:1996;2273-2276.
57. Trujillo M.A., Garewal H.S., Sampliner R.E. Nonsteroidal anti-inflammatory agents in chemoprevention of colorectal cancer. At what cost? Dig. Dis. Sci. 39:1994;2260-2266.
58. Giardiello F.M., Offerhaus G.J.A., DuBois R.N. The role of non-steroidal anti-inflammatory drugs in colorectal cancer prevention. Eur. J. Cancer. A31:1995;1076-1076.
59. McDade T.P., Perugini R.A., Vittimberga F.J. Jr., Carrigan R.C., Callery M.P. Salicylates inhibit NF-kB activation and enhance TNF-α-induced apoptosis in human pancreatic cancer cells. J. Surg. Res. 83:1999;56-61.
60. Tiano H.F., Loftin C.D., Akunda J.et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 62:2002;3395-3401.
61. Humes J.L., Winter C.A., Sadowski S.J., Kuehl F.A. Jr. Multiple sites on prostaglandin cyclooxygenase are determinants in the action of non-steroidal anti-inflammatory agents. Proc. Natl. Acad. Sci. USA. 78:1981;2053-2056.
62. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthase (cyclooxygenases)-1 and -2. J. Biol. Chem. 271:1996;33157-33160.
63. Goldman A.P., Williams C.S., Sheng H.et al. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis. 19:1998;2195-2199.
64. Futaki N., Yoshikawa K., Hamasaka Y., Arai I., Higuchi S., Lizuka H.et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects which causes minimal stomach lesions. Gen. Pharmacol. 24:1993;105-110.